Pathios Therapeutics

Pathios Therapeutics is an early-stage drug discovery company that was established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of tumour-associated macrophages (TAMs). The company is currently engaged in a fully... -enabled drug discovery program to identify novel small-molecule modulators of GPR65 with expected utility across a broad spectrum of cancers. The company is also more broadly interested in the potential to target GPR65 for benefit in a range of other serious diseases. Pathios employs a cutting-edge scientific approach to mapping the signalling of key GPCRs on immune cells based on human genetic insights, transcriptomics and state-of-the-art cellular immunology. By leveraging a range of proprietary insights emerging from this approach Pathios has identfied GPR65 as a key innate immune checkpoint on TAMs and now aims to rapidly deliver on the promise of novel therapeutic agents targeting this receptor. The company combines a team of experienced scientific leaders with a number of strategic external partnerships to efficiently carry out a range of drug discovery and scientific activities, capitalising on the very latest advances in GPCR drug discovery.Read More